

DISCLAIMER

This Molina Clinical Policy (MCP) is intended to facilitate the Utilization Management process. Policies are not a supplementation or recommendation for treatment; Providers are solely responsible for the diagnosis, treatment, and clinical recommendations for the Member. It expresses Molina's determination as to whether certain services or supplies are medically necessary, experimental, investigational, or cosmetic for purposes of determining appropriateness of payment. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered (e.g., will be paid for by Molina) for a particular Member. The Member's benefit plan determines coverage – each benefit plan defines which services are covered, which are excluded, and which are subject to dollar caps or other limits. Members and their Providers will need to consult the Member's benefit plan to determine if there are any exclusion(s) or other benefit limitations applicable to this service or supply. If there is a discrepancy between this policy and a Member's plan of benefits, the benefits plan will govern. In addition, coverage may be mandated by applicable legal requirements of a State, the Federal government or CMS for Medicare and Medicaid Members. CMS's Coverage Database can be found on the CMS website. The coverage directive(s) and criteria from an existing National Coverage Determination (NCD) or Local Coverage Determination (LCD) will supersede the contents of this MCP and provide the directive for all Medicare members. References included were accurate at the time of policy approval and publication.

OVERVIEW

Non-invasive positive pressure ventilation (NIPPV) refers to the delivery of mechanical positive pressure ventilatory support via a non-invasive interface (nasal mask, partial- or full-face mask, or nasal pillows), as opposed to an invasive interface (endotracheal tube or tracheostomy tube). The use of NIPPV has increased in the acute care hospital setting, the long-term care hospital, and the home for the management of patients with both acute respiratory failure and chronic respiratory failure requiring prolonged mechanical ventilation. Home NIPPV has been investigated for use in patients with obstructive lung disease, neuromuscular disease, obesity hypoventilation syndrome (OHS), and restrictive chest wall disease (Bach 2023; Gay 2024; ¹⁻²Hill & Kramer 2024; Martin 2024).

Both bilevel positive airway pressure (BPAP) devices and non-invasive ventilators can deliver NIPPV; however, their technical features may vary considerably. Key areas of variability include the mode of ventilation (pressure targeted versus volume targeted), monitoring capabilities, safety and alarm systems, and the presence of a flow sensor. Many home ventilators are multi-mode ventilators, capable of providing multiple modes of ventilation, including pressure control, volume control, assist/control, synchronized intermittent mandatory ventilation, BPAP, or continuous positive airway pressure (CPAP) and are capable of supporting patients invasively or non-invasively (Hyzy & Jia 2024).

Newer modes of NIPPV available on certain models of non-invasive ventilators include average volume-assured pressure support (AVAPS), average volume-assured pressure support auto-titrating expiratory positive airway pressure (AVAPS-AE), and intelligent volume-assured pressure support (iVAPS). AVAPS and iVAPS are the same mode of ventilation with the difference being trademarking of names: AVAPS is trademarked to Philips Respironics and iVAPS is trademarked to ResMed. AVAPS and iVAPS allow the clinician to set a target tidal volume, minimum and maximum inspiratory positive airway pressure, a backup respiratory rate, and an expiratory positive airway pressure. Each device has a specific algorithm that monitors the average achieved tidal volume, usually over the last rolling minute, and adjusts the inspiratory pressure in small increments to achieve the targeted tidal volume. The targeted tidal volume is typically achieved several minutes after initiation of therapy as it takes time for the device to “ramp up” to the patient's needs. AVAPS-AE functions similar to AVAPS and iVAPS with the addition of allowing the clinician to set a minimum and maximum expiratory pressure. The expiratory pressure will increase or decrease based on the device-specific algorithm and patient-specific needs as determined by the algorithm (Yarrarapu et al. 2023).

Considering the user's needs when selecting an appropriate positive pressure ventilation assist device is essential. For situations in which there is a risk of acute respiratory failure, hypoventilation, or apnea, the non-invasive ventilator will sound an alarm where the home BPAP unit may not. Additionally, non-invasive ventilators have the capability of delivering ventilation based on volume and precise levels of oxygen needed by more complex patients (Hyzy & Jia 2024; Yarrarapu et al. 2023).

Regulatory Status

Multiple ventilators are available for NIPPV use within a facility (acute care hospital or long-term care facility) or the home setting. Certain ventilators have FDA-approval for use within both settings. Ventilators approved for continuous use within a facility may be found in the FDA 510(k) database by searching product code “CBK”. Ventilators approved for home use may be found by using the subsequent product code “NOU.”

COVERAGE POLICY

This policy does not address the use of other respiratory assist devices including bilevel positive airway pressure (BPAP) or continuous positive airway pressure (CPAP) devices. Please see Milliman MCG for criteria for BPAP and CPAP devices. These devices are considered first line treatment for many conditions and should be tried before following the criteria outlined below whenever appropriate.

Non-invasive positive pressure ventilation (NIPPV) with a ventilator approved by the FDA for home use may be **considered medically necessary** when ONE of the following criteria are met:

1. **Diagnosis of chronic respiratory failure due to progressive neuromuscular disease** (e.g., muscular dystrophies, poliomyelitis, multiple sclerosis, spinal cord injuries, spinal muscular atrophy, diaphragmatic paralysis, myasthenia gravis, amyotrophic lateral sclerosis) or severe chest wall disorder (e.g., kyphoscoliosis, asphyxiating thoracic dystrophy)
2. **Mechanical ventilation required due to respiratory insufficiency** with **one or more** of the following:
 - a. Arterial oxygen (O₂) saturation < 88% for 5 consecutive minutes during nocturnal oximetry
 - b. Arterial partial pressure of carbon dioxide (PaCO₂) ≥ 45 mm Hg (6.0 kPa)
 - c. Maximal inspiratory pressures < 60 cm/H₂O
 - d. Forced vital capacity < 50% predicted
3. **Diagnosis of chronic obstructive pulmonary disease (COPD)** and **one or more** of the following:
 - a. Palliative care in patient with end-stage disease and advance directive stating no desire for intubation
 - b. Chronic hypercapnia and **ALL** the following:
 - i. Patient has documented failure of BPAP (including both simple and advanced modes, such as average volume-assured pressure support [AVAPS] and intelligent volume-assured pressure support [iVAPS]) to improve hypercapnia and/or oxygen saturation level
 - ii. Prescription for a non-invasive ventilator is written by a pulmonologist (or arrangements have been made for pulmonary follow-up within 3 months)
4. **Diagnosis of Obesity Hypoventilation Syndrome (OHS)** and **ALL** the following:
 - a. Body mass index ≥ to 30 kg/m²
 - b. Daytime hypercapnia with PaCO₂ greater than 45 mmHg (6.0 kPa) without other etiology (e.g., kyphoscoliosis, lung parenchymal disease, myopathy, severe hypothyroidism)
 - c. Sleep-disordered breathing or hypoventilation on polysomnography, as indicated by **one or more** of the following:
 - i. Apnea-hypopnea index of ≥ 5
 - ii. Increase in PaCO₂ during sleep by more than 10 mm Hg (1.3 kPa) above value while awake
 - iii. Significant oxygen desaturation (e.g., O₂ < 90%) not explained by obstructive apneas or hypopneas
 - iv. TSH level does not demonstrate hypothyroidism
 - d. Failure to improve arterial oxygen saturations and/or hypercapnia on CPAP or BPAP devices
 - e. Diagnosis and prescription for the device must be made by a pulmonologist or other relevant specialty physician
 - f. The NIPPV device is FDA approved for the clinical indication(s)
 - g. None of the following conditions are present:
 - i. Alteration in level of consciousness (i.e., alert and oriented)
 - ii. Anatomic abnormality that precludes mask fitting (facial or neurological surgery, trauma, or deformity)
 - iii. High risk for aspiration (excessive secretions, impaired cough, or inability of mechanically assisted cough to clear secretions)
 - iv. Swallowing disorder
 - v. Inability to cooperate/protect airway
 - vi. Upper airway obstruction
5. **A BPAP or CPAP device is not appropriate** when the Member meets **one or more** of the criteria below:

Molina Clinical Policy

Noninvasive Positive Pressure Ventilation: Policy No. 275

Last Approval: 12/11/2024

Next Review Due By: December 2025



- a. Chronic respiratory insufficiency fails to improve with a BPAP device (both simple and advanced modes)
- b. Settings or functionality required by patient is not available with a BPAP device (both simple and advanced modes), as indicated by **one or more** of the following:
 - i. Alarms required by patient are not available on a BPAP device
 - ii. Daytime ventilation using mouthpiece required
 - iii. The pressure range delivered by the device (e.g., expiratory or inspiratory pressure) is not appropriate for the patient
 - iv. Volume-assured pressure support (e.g., AVAPS or iVAPS) or volume control mode is required (e.g., OHS)
- c. Ventilated patient requires cough assistance via volume ventilator's breath stacking capability
- d. Ventilation is required 24 hours a day

** Per coding guidelines, when BPAP is documented and performed, CPT 94660 (Continuous positive airway pressure ventilation (CPAP), initiation and management) is the appropriate code as BPAP is a non-invasive mechanical ventilation that includes (CPAP) and pressure support ventilation

Continuation of Therapy

For establishment of **continued medical necessity** beyond 3 months, the medical records should document that the member has been compliantly using the device (an average of 4 hours per 24-hour period, and that the member is benefiting from its use. Approval of continuation of use also requires that indications for the initial approval above are still be met. The following are required for continuation review:

1. Compliance with use is reported every three months including documentation of compliant use of the device monitor for an average of 4 or more hours per 24 hours (includes documentation from the requesting provider stating continued benefit of use)
2. Initial rental authorization of the device is for 90 days. Compliance is confirmed using a smartcard or other similar report. This verification should be completed within the first 90 days of therapy to assist with long-term rental authorizations. (Note: Smartcards are an important part of NIPPV management and are not separately reimbursable)
3. Documentation of a specialist referral
4. Documentation of symptomatic improvement with the use of a ventilator
5. Documentation of a sleep study if treatment is for severe obstructive sleep apnea
6. Documentation of pulmonary function tests and/or arterial blood gases if treatment is for severe COPD or OHS

Limitations and Exclusions

Home non-invasive positive pressure ventilators are excluded and **not medically necessary** for the treatment of **ANY** of the following conditions or scenarios:

1. Obstructive sleep apnea as the clinical outcomes have not been shown to be superior to other standard treatments (e.g., CPAP, BPAP)
2. Other conditions/diseases, including but not limited to cystic fibrosis, due to insufficient evidence in the peer reviewed medical publications
3. Chronic stable COPD without hypercapnia, and central sleep apnea or heart failure
4. Acute respiratory distress syndrome
5. Ventilation is required continuously (24 hours/day)

Due to limited evidence-based support, contraindications include, but are not limited to:

1. Altered mental status or confusion
2. Drowsiness or loss of consciousness
3. Excessive mucus production or respiratory secretion
4. Facial trauma or other abnormalities
5. Hemodynamic instability
6. Nausea and/or vomiting
7. Respiratory arrest

DOCUMENTATION REQUIREMENTS. Molina Healthcare reserves the right to require that additional documentation be made available as part of its coverage determination; quality improvement; and fraud; waste and abuse prevention processes. Documentation required may include, but is not limited to, patient records, test results and credentials of the provider ordering or performing a drug or service. Molina Healthcare may deny reimbursement or take additional appropriate action if the documentation provided does not support the initial determination that the drugs or services were medically necessary, not investigational, or experimental, and otherwise within the scope of benefits afforded to the member, and/or the documentation demonstrates a pattern of billing or other practice that is inappropriate or excessive.

SUMMARY OF MEDICAL EVIDENCE

Neuromuscular or Chest Wall Disorders

Systematic Reviews and Meta-Analyses

Delorme et al. (2023) completed a systematic review and meta-analysis to determine if the intensity of home non-invasive ventilator settings affected outcomes in patients with neuromuscular or chest-wall disorders. Non-invasive ventilator intensity was defined as “the product of pressure support (or tidal volume) and backup rate.” The primary outcome was diurnal PaCO₂ levels with secondary outcomes being daily non-invasive ventilator usage, interface type, nocturnal oxygenation, and sleep quality. A total of seven studies with 192 participants (n=113 neuromuscular, n=63 chest wall disorder) were included in the analysis. Results for diurnal PaCO₂ levels showed that the intensity of non-invasive ventilator settings was not associated with significant differences in PaCO₂ levels. However, a greater amount of daily usage was associated with lower PaCO₂ levels as was lower baseline PaCO₂ values. Regarding oxygenation, higher partial pressure of arterial oxygen (PaO₂) levels were associated with higher baseline PaO₂ values and higher daily usage. Disease category (neuromuscular vs. chest wall disorders) was associated with whether non-invasive ventilator setting intensity impacted PaO₂ levels. Researchers noted greater reductions in PaCO₂ values in higher baseline PaCO₂ values and higher non-invasive ventilator setting intensity in patients with chest wall disorders. The PaO₂ levels of patients with neuromuscular disorders was negatively impacted by more intense non-invasive ventilator settings while patients with chest wall disorders typically experienced an improvement in PaO₂ levels. There was no significant association noted between non-invasive ventilator setting intensity and interface type or daily non-invasive ventilator usage.

Cystic Fibrosis

Non-Randomized Studies, Retrospective Reviews, and Other Evidence

Milross et al. (2019) completed a prospective, randomized, parallel group study to evaluate if NIPPV with supplemental oxygen reduced the development of hypercapnia or criteria for failure of therapy over 12 months compared to low-flow oxygen therapy alone in patients with cystic fibrosis and oxygen desaturation. A total of 29 patients were included in the study with 14 being randomized to NIPPV with supplemental oxygen and 15 being randomized to low-flow oxygen therapy. Patients received follow-up at 3, 6, and 12 months. The primary outcome was event free survival, defined as failure of therapy (PaCO₂ > 60 mmHg, increase in PaCO₂ > 10mmHg from baseline, or an increase in TcCO₂ > 10 mmHg from awake to sleep or sleep rises in TcCO₂ > 10mmHg), lung transplantation, or death. NIPPV with supplemental oxygen was associated with a significantly higher likelihood of event-free survival (33% at 3 months, 26% at 6 months, and 46% at 12 months) and a lower likelihood of failure of therapy. The number of transplants at each follow-up was cumulative (included the number of transplants from the previous follow-up) and for each follow-up period (3, 6, and 12 months respectively) was 0, 2, and 2 for the NIPPV with supplemental oxygen group and 4, 4, and 5 for the low-flow oxygen therapy group. The number of patients meeting failure of therapy criteria was also cumulative and for each follow-up period (3, 6, and 12 months respectively) was 1, 2, and 4 for the low-flow oxygen therapy group while no patients in the NIPPV with supplemental oxygen group met criteria for failure of therapy. There were no differences noted between either group in terms of arterial blood gases, pulmonary function tests, and hospitalizations. Researchers noted that the small sample size of this study did not allow for demonstration of clinically relevant differences in PaCO₂. Researchers also noted certain subgroups of patients with cystic fibrosis may benefit from NIPPV. However, additional high-quality studies with larger sample sizes are needed to verify the results of this study and to determine which subgroups would have the most benefit.

Archangelidi et al. (2019) completed a retrospective review of the UK Cystic Fibrosis Registry to determine the patterns of NIPPV usage, the changes in forced expiratory volume in one second associated with NIPPV use, and the survival of patients following initiation of NIPPV therapy. A total of 1,107 patients in the registry had at least one record with documented NIPPV usage. Adults (age > 16 years) with significantly worse lung function (forced expiratory volume in one second < 40% of predicted) at baseline were noted to have a greater increase in forced expiratory volume in one second following initiation of NIPPV therapy. However, the risk of death and transplant was not impacted by the

initiation of NIPPV and was noted to be worse compared to the overall cohort with “approximately 36% of those with at least one non-invasive ventilation record [dying] by the end of follow-up [and] 40% accepted for lung transplant.” Researchers noted a potential bias by indication despite bias mitigation using statistical methods as patients with advanced cystic fibrosis were likely to have exhausted treatment options prior to the initiation of NIPPV.

Obesity Hypoventilation Syndrome (OHS)

Randomized Controlled Trials

Masa et al. (2019) conducted an open label, randomized controlled trial to assess the effectiveness of continuous positive airway pressure (CPAP) versus non-invasive positive pressure ventilation (NIPPV) in patients with obesity hypoventilation syndrome (OHS). Participants were eligible if they were 15-80 years old, had untreated OHS, and an apnea-hypopnea index of 30 or more events per hour. The analysis included 97 patients in the NIPPV group and 107 in the CPAP group. The primary outcome was the number of hospitalization days per year. At a median follow-up of 5.44 years, the CPAP group had an average of 1.63 hospitalization days per patient-year, while the NIPPV group had 1.44 days. Reported adverse events were similar between the groups. The authors concluded that in stable patients with OHS and severe obstructive sleep apnea, both NIPPV and CPAP are similarly effective over the long term. However, due to its lower complexity and cost, CPAP may be the preferred initial treatment until further studies are conducted.

Chronic Obstructive Pulmonary Disease (COPD)

Systematic Review and Meta-Analysis

Raveling et al. (2021) conducted an updated systematic review to assess the effects of chronic NIPPV at home in people with COPD. The authors included RCTs comparing chronic nocturnal NIPPV in addition to standard care versus standard care alone. Studies investigating people initiated on NIPPV in a stable phase and studies investigating NIPPV commenced after a severe COPD exacerbation were reported and analyzed separately. The primary outcomes evaluated were arterial blood gases, health-related quality of life, exercise capacity (stable COPD), and admission-free survival (post-exacerbation COPD). Secondary outcomes for both populations included lung function, COPD exacerbations and admissions, and all-cause mortality. A total of 21 studies (including 778 people with stable COPD and 364 people with post-exacerbation COPD) met inclusion criteria. Results showed that in all people with COPD who had hypercapnia, chronic NIPPV for 3- and 12- months improved blood gases. In stable COPD, chronic NIPPV also might have improved quality of life, and survival seemed to be better compared to people who were treated with standard care only. There was no relevant benefit of NIPPV on exercise capacity. People using chronic NIPPV after a COPD admission experienced less benefit; carbon dioxide levels decreased, the time to the next hospital admission might have been longer when treated with NIPPV but quality of life and survival were not affected by chronic NIPPV. Confidence in the certainty was good in relation to blood gases. For other outcomes, certainty of the evidence is moderate to very low due to participants and researchers not being blinded.

¹Wilson et al. (2020) completed a meta-analysis and systematic review to “evaluate the association of home NIPPV via BPAP devices and non-invasive home mechanical ventilator devices with clinical outcomes and adverse events in patients with COPD and hypercapnia.” The analysis included a total of 51,085 patients with COPD and hypercapnia. The analysis found that BPAP compared to no device was associated with significantly lower mortality risk (22.31% compared to 28.57%). The need for intubation was also significantly lower (5.34% vs 14.71%) as was all-cause hospital admissions (39.74% vs 75.00%). The use of home BPAP was also associated with fewer emergency department visits, ICU admissions, less dyspnea, and a longer distance on the shuttle walk test. Only two observational studies compared non-invasive home mechanical ventilator use to no device. Analysis showed that non-invasive home mechanical ventilator use was also associated with significantly fewer all-cause hospital admissions but no statistically significant difference in mortality (21.84% vs 34.09%). A total of 23 studies compared NIPPV usage (BPAP and non-invasive home mechanical ventilator devices combined) to no device. NIPPV usage was also associated with significantly lower risk of mortality (22.26% vs 29.20%), lower all-cause hospital admissions (39.74% vs 75.00%), and lower need for intubation (5.34% vs 14.71%). One included RCT (n=40 participants) compared BPAP volume assured pressure support to standard BPAP in terms of mortality and found BPAP volume assured pressure support to be associated with lower mortality (5.00% vs 10.00%), although the overall strength of evidence was determined to be insufficient. One RCT (n=49 participants) compared BPAP to CPAP and found BPAP was associated with fewer exacerbations (30.43% vs 53.85%). Non-invasive home mechanical ventilator usage was compared to CPAP in one RCT (n=39,700 participants) and found that non-invasive home mechanical ventilator usage was associated with significantly less all-cause hospital admissions (p<0.001) and hospital admissions due to respiratory causes (p=0.01). However, the quality of evidence was determined to be low.

National and Specialty Organizations

The **Global Initiative for Chronic Obstructive Lung Disease (GOLD)** published its 2025 report with the following recommendations for the use of long-term NIPPV in patients with COPD (GOLD 2024):

- Long-term NIPPV may decrease mortality and prevent re-hospitalization for patients with severe chronic hypercapnia and a history of respiratory failure-related hospitalization(s).
- The need for NIPPV support should be considered individually and an action plan for treatment should be developed and updated as needed.
- The use of NIPPV with home oxygen may significantly prolong the time to hospital readmission or death.
- NIPPV should be prescribed and monitored by clinicians that are familiar with the devices utilized.

An **American Thoracic Society (ATS)** Clinical Practice Guideline on Long-Term Non-invasive Ventilation in Chronic Stable Hypercapnic COPD (Macrea et al. 2020) provides the following five evidence-based recommendations:

- We suggest the use of nocturnal NIPPV in addition to usual care for patients with chronic stable hypercapnic COPD (conditional recommendation, moderate certainty).
- We suggest that patients with chronic stable hypercapnic COPD undergo screening for obstructive sleep apnea before initiation of long-term NIPPV (conditional recommendation, very low certainty).
- We suggest not initiating long-term NIPPV during an admission for acute-on-chronic hypercapnic respiratory failure, favoring instead reassessment for NIPPV at 2–4 weeks after resolution (conditional recommendation, low certainty); 4) we suggest not using an in-laboratory overnight polysomnogram to titrate NIPPV in patients with chronic stable hypercapnic COPD who are initiating NIPPV (conditional recommendation, very low certainty).
- We suggest NIPPV with targeted normalization of PaCO₂ in patients with hypercapnic COPD on long-term NIPPV (conditional recommendation, low certainty).

The **American Thoracic Society (ATS)** published *Clinical Practice Guideline for the Evaluation and Management of Obesity Hypoventilation Syndrome* (Mokhlesi et al. 2019). The guideline provides the following recommendations:

- We suggest clinicians use a serum bicarbonate level <27 mmol/L to exclude the diagnosis of OHS in obese patients with sleep-disordered breathing when suspicion for OHS is not very high (<20%) but to measure arterial blood gases in patients strongly suspected of having OHS.
- We suggest stable ambulatory patients with OHS receive positive airway pressure.
- We suggest CPAP rather than non-invasive ventilation be offered as the first-line treatment to stable ambulatory patients with OHS and coexistent severe obstructive sleep apnea.
- We suggest patients hospitalized with respiratory failure and suspected of having OHS be discharged with non-invasive ventilation until they undergo outpatient diagnostic procedures and positive airway pressure titration in the sleep laboratory (ideally within 2–3 months).
- We suggest nocturnal home therapy with NIPPV be offered if CPAP/BPAP fail to correct hypoventilation.
- We suggest patients with OHS use weight-loss interventions that produce sustained weight loss of 25% to 30% of body weight to achieve resolution of OHS (which is more likely to be obtained with bariatric surgery).

The **National Institute for Health and Clinical Excellence (NICE)** guideline NG115 (2019) on COPD diagnosis and management states, “Refer people who are adequately treated but have chronic hypercapnic respiratory failure and have needed assisted ventilation (whether invasive or non-invasive) during an exacerbation, or who are hypercapnic or acidotic on long-term oxygen therapy, to a specialist center for consideration of long-term non-invasive ventilation.”

A technology assessment prepared for the **Agency for Healthcare Research and Quality (AHRQ)** by the Mayo Clinic Evidence-based Practice Center (Wilson et al. 2020) evaluated the use of NIPPV in adult patients with chronic respiratory failure due to a variety of primary causes including COPD, thoracic restrictive disorders, neuromuscular disease, and OHS. Randomized and comparative nonrandomized studies that enrolled adults with chronic respiratory failure who used NIPPV for ≥ 1 month at home using a home mechanical ventilator, BPAP device, or CPAP device were selected for inclusion, resulting in a total of 68 studies evaluating 53,733 patients. Study limitations include the inability to fully account for the type of device used, equipment settings, and other respiratory services provided. The following conclusions were made:

- In patients with COPD, home BPAP (compared to no device) was associated with lower mortality, decreased need for intubations, fewer patients with hospital admissions but no difference in the total number of hospital admissions or quality of life.

Molina Clinical Policy

Noninvasive Positive Pressure Ventilation: Policy No. 275

Last Approval: 12/11/2024

Next Review Due By: December 2025



- In patients with stable COPD, NIPPV compared with no device was associated with no difference in the total number of hospital admissions.
- In patients with COPD and recent exacerbation, NIPPV compared with no device was associated with no difference in mortality (OR=0.66, 95% CI: 0.41 to 1.06), but was associated with fewer hospital admissions
- In patients with thoracic restrictive diseases, home mechanical ventilators (compared to no device) were associated with lower mortality.
- In patients with neuromuscular diseases, home BPAP (compared to no device) was associated with lower mortality and better quality of life.
- In patients with OHS, home mechanical ventilators or BPAP (compared to no device) was associated with lower mortality.

The assessment also proposes that future research should look to determine which patient populations would benefit from a home mechanical ventilator versus BPAP device, when to optimally initiate treatment, comparative effectiveness of invasive versus non-invasive 24-hour ventilation, and the consequence of various features and device types on outcomes. The authors note that although RCTs may offer the highest level of evidence, enrolling patients requiring this type of treatment may not be ethical. Thus, other study designs, such as single arm interventional studies, may be the best available option.

The **European Respiratory Society** published a 2019 guideline titled *Long-Term Home Non-Invasive Ventilation for Management of COPD*. The following evidence-based recommendations were made regarding the clinical application of non-invasive ventilation in chronic hypercapnic COPD patients (Ergan et al. 2019):

- Use of non-invasive ventilation in stable hypercapnic COPD.
- Use of non-invasive ventilation in COPD patients following a COPD exacerbation requiring acute non-invasive ventilation.
- Use of non-invasive ventilation settings targeting a reduction in carbon dioxide.
- Using fixed pressure support as first choice ventilator mode.

SUPPLEMENTAL INFORMATION

Chronic hypercapnia defined as PaCO₂ ≥ 50 mm Hg (6.7 kPa).

Non-invasive positive pressure ventilation may be abbreviated as either NIPPV or NPPV. In addition, non-invasive ventilation, or NIV, may also refer to non-invasive positive pressure ventilation. However, NIV may also refer to non-invasive negative pressure ventilation. The type of ventilation (negative or positive) used typically depends on the disease process. In addition, some studies refer to NIPPV as simply non-invasive ventilation or NIV. NIPPV was used throughout this policy to provide clarity and prevent confusion.

Bilevel positive airway pressure is often abbreviated as BiPAP. However, it is important to note that BiPAP is the trademarked name of a specific device. BPAP and BiPAP refer to the same therapy and BPAP was used throughout this policy to prevent reference to a specific device.

CODING & BILLING INFORMATION

HCPCS (Healthcare Common Procedure Coding System)

Code	Description
E0466	Home ventilator, any type, used with noninvasive interface (e.g., mask, chest shell)
E0467	Home ventilator, multi-function respiratory device, also performs any or all of the additional functions of oxygen concentration, drug nebulization, aspiration, and cough stimulation, includes all accessories, components and supplies for all functions
E0468	Home ventilator, dual-function respiratory device, also performs additional function of cough stimulation, includes all accessories, components and supplies for all functions

CODING DISCLAIMER. Codes listed in this policy are for reference purposes only and may not be all-inclusive. Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement. Listing of a service or device code in this policy does not guarantee coverage. Coverage is determined by the benefit document. Molina adheres to Current Procedural Terminology (CPT®), a registered

Molina Clinical Policy

Noninvasive Positive Pressure Ventilation: Policy No. 275

Last Approval: 12/11/2024

Next Review Due By: December 2025



trademark of the American Medical Association (AMA). All CPT codes and descriptions are copyrighted by the AMA; this information is included for informational purposes only. Providers and facilities are expected to utilize industry standard coding practices for all submissions. When improper billing and coding is not followed, Molina has the right to reject/deny the claim and recover claim payment(s). Due to changing industry practices, Molina reserves the right to revise this policy as needed.

APPROVAL HISTORY

12/11/2024	Policy reviewed. No changes to coverage criteria. Updated Summary of Medical Evidence and References.
12/13/2023	Policy reviewed, no changes to criteria. Updated Overview, Summary of Medical Evidence, Supplemental Information, and References.
12/14/2022	Policy reviewed, updated Coverage Policy – included criteria for patients with COPD and for those when BPAP/CPAP is not indicated; added Continuation of Therapy section. IRO Peer Review on October 11, 2022, by a practicing, board-certified physician with specialties in the areas of Pulmonary Disease and Critical Care. IRO Peer review on December 12, 2022, by a practicing, board-certified physician with specialties in the area of Pulmonary Disease.
02/09/2022	Policy reviewed; updated Coverage Policy, Summary of Evidence, and Reference section.
02/08/2021	Policy reviewed, updated references.
04/23/2020	Policy reviewed, updated references.
09/18/2019	Policy reviewed, Summary of Evidence and Reference section updated.
07/16/2018	Policy reviewed; updated Coverage Policy, Summary of Evidence, and Reference section. Added medically necessary criteria for the diagnosis of COPD and chronic restrictive hypoventilation syndrome related to obesity.
12/13/2017	Policy reviewed, no changes to criteria, updated references.
05/23/2016	New policy.

REFERENCES

1. Archangelidi O, Carr SB, Simmonds NJ, et al. Non-invasive ventilation and clinical outcomes in cystic fibrosis: Findings from the UK CF registry. *J Cyst Fibros*. 2019 Sep;18(5):665-670. doi: 10.1016/j.jcf.2018.11.006. Epub 2018 Nov 28. PMID: 30503032.
2. Bach JR. Noninvasive ventilatory support and mechanical insufflation-exsufflation for patients with respiratory muscle dysfunction. Updated March 2, 2023. Accessed November 11, 2024. www.uptodate.com.
3. Centers for Medicare & Medicaid Services (CMS). Medicare coverage database. National coverage determination – durable medical equipment reference list (ver. 3) (280.1). Effective Date May 16, 2023. Accessed November 11, 2024. <https://www.cms.gov/medicare-coverage-database/search.aspx>.
4. Delorme M, Leotard A, Lebret M, et al. Effect of intensity of home noninvasive ventilation in individuals with neuromuscular and chest wall disorders: A systematic review and meta-analysis of individual participant data. *Arch Bronconeumol*. 2023 Aug;59(8):488-496. English, Spanish. doi: 10.1016/j.arbres.2023.05.002. Epub 2023 May 11. PMID: 37217384.
5. Ergan B, Oczkowski S, Rochweg B, et al. European Respiratory Society guidelines on long-term home non-invasive ventilation for management of COPD. *Eur Respir J*. 2019 Sep 28;54(3):1901003. doi: 10.1183/13993003.01003-2019. PMID: 31467119.
6. Gay PC. Nocturnal ventilatory support in COPD. Updated June 27, 2024. Accessed November 11, 2024. www.uptodate.com.
7. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD: 2025 report. Published 2024. Accessed November 11, 2024. <https://goldcopd.org/2025-gold-report/>.
8. ¹Hill NS, Kramer NR. Noninvasive ventilation in adults with chronic respiratory failure from neuromuscular and chest wall diseases: Patient selection and alternative modes of ventilatory support. Updated January 18, 2024. Accessed November 11, 2024. www.uptodate.com.
9. ²Hill NS, Kramer NR. Noninvasive ventilation in adults with chronic respiratory failure from neuromuscular and chest wall diseases: Practical aspects of initiation. Updated April 1, 2024. Accessed November 11, 2024. www.uptodate.com.
10. Hyzy RC, Jia S. Modes of mechanical ventilation. Updated May 23, 2024. Accessed November 11, 2024. www.uptodate.com.
11. Macrea M, Oczkowski S, Rochweg B, et al. Long-term noninvasive ventilation in chronic stable hypercapnic chronic obstructive pulmonary disease: An official American Thoracic Society clinical practice guideline. *Am J Respir Crit Care Med*. 2020 Aug 15;202(4): e74-e87. doi: 10.1164/rccm.202006-2382ND. PMID: 32795139; PMCID: PMC7427384.
12. Martin TJ. Noninvasive positive airway pressure therapy for the obesity hypoventilation syndrome. Updated March 4, 2024. Accessed November 11, 2024. www.uptodate.com.
13. Masa JF, Mokhlesi B, Benítez I, et al. Long-term clinical effectiveness of continuous positive airway pressure therapy versus non-invasive ventilation therapy in patients with obesity hypoventilation syndrome: a multicentre, open-label, randomised controlled trial. *Lancet*. 2019 Apr 27;393(10182):1721-1732. doi: 10.1016/S0140-6736(18)32978-7. Epub 2019 Mar 29. PMID: 30935737.
14. Milross MA, Piper AJ, Dwyer TJ, et al. Non-invasive ventilation versus oxygen therapy in cystic fibrosis: A 12-month randomized trial. *Respirology*. 2019 Dec;24(12):1191-1197. doi: 10.1111/resp.13604. Epub 2019 Jun 17. PMID: 31206975.
15. Mokhlesi B, Masa JF, Brozek JL, et al. Evaluation and management of obesity hypoventilation syndrome: An official American Thoracic Society clinical practice guideline. *Am J Respir Crit Care Med*. 2019 Aug 1;200(3): e6-e24. doi: 10.1164/rccm.201905-1071ST. Erratum in: *Am J Respir Crit Care Med*. 2019 Nov 15;200(10):1326. PMID: 31368798; PMCID: PMC6680300.
16. National Institute for Health and Clinical Excellence (NICE). Chronic obstructive pulmonary disease in over 16s: diagnosis and management NICE guideline [NG115]. Published December 5, 2018. Updated July 26, 2019. Accessed November 11, 2024. <https://www.nice.org.uk/guidance/ng115>.
17. National Institute for Health and Clinical Excellence (NICE). Motor neurone disease: assessment and management. NICE guideline [NG42]. Published February 24, 2016. Updated July 23, 2019. Accessed November 11, 2024. <https://www.nice.org.uk/guidance/ng42>
18. Raveling T, Vonk J, Struik FM, et al. Chronic non-invasive ventilation for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*. 2021 Aug 9;8(8):CD002878. doi: 10.1002/14651858.CD002878.pub3. PMID: 34368950; PMCID: PMC8407093.
19. ¹Wilson ME, Dobler CC, Morrow AS, Beuschel B, Alsawas M, Benkhadra R, Seisa M, Mittal A, Sanchez M, Daraz L, Holets S, Murad MH, Wang Z. Association of Home Noninvasive Positive Pressure Ventilation With Clinical Outcomes in Chronic Obstructive Pulmonary Disease:

Molina Clinical Policy

Noninvasive Positive Pressure Ventilation: Policy No. 275

Last Approval: 12/11/2024

Next Review Due By: December 2025



- A Systematic Review and Meta-analysis. JAMA. 2020 Feb 4;323(5):455-465. doi: 10.1001/jama.2019.22343. PMID: 32016309; PMCID: PMC7042860.
20. ²Wilson M, Wang Z, Dobler CC, et al. Noninvasive positive pressure ventilation in the home (with addendum). Technology Assessment Project ID: PULT0717. Rockville (MD): Agency for Healthcare Research and Quality (US); Apr 2, 2020. <https://www.ncbi.nlm.nih.gov/books/NBK575998/>.
 21. United States Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH). 510(k) premarket notification database (search. K083526, K082966, K093416, K111146, K111610). Accessed November 11, 2024. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm>.
 22. Yarrarapu SNS, Saunders H, Sanghavi DK, et al. Average volume-assured pressure support. In: StatPearls [Internet]. Treasure Island (FL). Updated August 8, 2023. Accessed November 11, 2024. <https://www.ncbi.nlm.nih.gov/books/NBK560600/>.